These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 27290681)

  • 1. Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease.
    Escaned J; Banning A; Farooq V; Echavarria-Pinto M; Onuma Y; Ryan N; Cavalcante R; Campos CM; Stanetic BM; Ishibashi Y; Suwannasom P; Kappetein AP; Taggart D; Morel MA; van Es GA; Serruys PW
    EuroIntervention; 2016 Jun; 12(2):e224-34. PubMed ID: 27290681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study.
    Escaned J; Collet C; Ryan N; De Maria GL; Walsh S; Sabate M; Davies J; Lesiak M; Moreno R; Cruz-Gonzalez I; Hoole SP; Ej West N; Piek JJ; Zaman A; Fath-Ordoubadi F; Stables RH; Appleby C; van Mieghem N; van Geuns RJ; Uren N; Zueco J; Buszman P; Iñiguez A; Goicolea J; Hildick-Smith D; Ochala A; Dudek D; Hanratty C; Cavalcante R; Kappetein AP; Taggart DP; van Es GA; Morel MA; de Vries T; Onuma Y; Farooq V; Serruys PW; Banning AP
    Eur Heart J; 2017 Nov; 38(42):3124-3134. PubMed ID: 29020367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II trial.
    Campos CM; Stanetic BM; Farooq V; Walsh S; Ishibashi Y; Onuma Y; Garcia-Garcia HM; Escaned J; Banning A; Serruys PW;
    Catheter Cardiovasc Interv; 2015 Nov; 86(6):E229-38. PubMed ID: 25946686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial.
    Head SJ; Davierwala PM; Serruys PW; Redwood SR; Colombo A; Mack MJ; Morice MC; Holmes DR; Feldman TE; Ståhle E; Underwood P; Dawkins KD; Kappetein AP; Mohr FW
    Eur Heart J; 2014 Oct; 35(40):2821-30. PubMed ID: 24849105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.
    Banning AP; Serruys P; De Maria GL; Ryan N; Walsh S; Gonzalo N; Jan van Geuns R; Onuma Y; Sabate M; Davies J; Lesiak M; Moreno R; Cruz-Gonzalez I; Hoole SP; Piek JJ; Appleby C; Fath-Ordoubadi F; Zaman A; Van Mieghem NM; Uren N; Zueco J; Buszman P; Iniguez A; Goicolea J; Hildick-Smith D; Ochala A; Dudek D; de Vries T; Taggart D; Farooq V; Spitzer E; Tijssen J; Escaned J
    Eur Heart J; 2022 Mar; 43(13):1307-1316. PubMed ID: 34617993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II.
    Campos CM; van Klaveren D; Farooq V; Simonton CA; Kappetein AP; Sabik JF; Steyerberg EW; Stone GW; Serruys PW;
    Eur Heart J; 2015 May; 36(20):1231-41. PubMed ID: 25583761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.
    Mohr FW; Morice MC; Kappetein AP; Feldman TE; Ståhle E; Colombo A; Mack MJ; Holmes DR; Morel MA; Van Dyck N; Houle VM; Dawkins KD; Serruys PW
    Lancet; 2013 Feb; 381(9867):629-38. PubMed ID: 23439102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.
    Cohen DJ; Osnabrugge RL; Magnuson EA; Wang K; Li H; Chinnakondepalli K; Pinto D; Abdallah MS; Vilain KA; Morice MC; Dawkins KD; Kappetein AP; Mohr FW; Serruys PW;
    Circulation; 2014 Sep; 130(14):1146-57. PubMed ID: 25085960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation.
    Takahashi K; Serruys PW; Fuster V; Farkouh ME; Spertus JA; Cohen DJ; Park SJ; Park DW; Ahn JM; Kappetein AP; Head SJ; Thuijs DJ; Onuma Y; Kent DM; Steyerberg EW; van Klaveren D;
    Lancet; 2020 Oct; 396(10260):1399-1412. PubMed ID: 33038944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial.
    Kappetein AP; Serruys PW; Sabik JF; Leon MB; Taggart DP; Morice MC; Gersh BJ; Pocock SJ; Cohen DJ; Wallentin L; Ben-Yehuda O; van Es GA; Simonton CA; Stone GW
    EuroIntervention; 2016 Sep; 12(7):861-72. PubMed ID: 27639738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and pattern of de-novo three-vessel and left main coronary artery disease; insights from single center enrolment in the SYNTAX study.
    Rastan AJ; Boudriot E; Falk V; Kappetein AP; Borger MA; Serruys PW; Schuler G; Mohr FW
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):376-82; discussion 382-3. PubMed ID: 18579392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: two-year follow-up of the SYNTAX II study.
    Serruys PW; Kogame N; Katagiri Y; Modolo R; Buszman PE; Íñiguez-Romo A; Goicolea J; Hildick-Smith D; Ochala A; Dudek D; Piek JJ; Wykrzykowska JJ; Escaned J; Banning AP; Farooq V; Onuma Y
    EuroIntervention; 2019 Jun; 15(3):e244-e252. PubMed ID: 30636684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
    Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients.
    Piccolo R; Pilgrim T; Heg D; Franzone A; Rat-Wirtzler J; Räber L; Silber S; Serruys PW; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1657-66. PubMed ID: 26585615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.
    Chen SL; Han YL; Zhang YJ; Ye F; Liu HW; Zhang JJ; Xu B; Jiang TM; Zhou YJ; Lv SZ
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1233-41. PubMed ID: 24239199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, correlates, and significance of abnormal cardiac enzyme rises in patients treated with surgical or percutaneous based revascularisation: a substudy from the Synergy between Percutaneous Coronary Interventions with Taxus and Cardiac Surgery (SYNTAX) Trial.
    Farooq V; Serruys PW; Vranckx P; Bourantas CV; Girasis C; Holmes DR; Kappetein AP; Mack M; Feldman T; Morice MC; Colombo A; Morel MA; de Vries T; Dawkins KD; Mohr FW; James S; Ståhle E
    Int J Cardiol; 2013 Oct; 168(6):5287-92. PubMed ID: 23993326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.
    Thuijs DJFM; Kappetein AP; Serruys PW; Mohr FW; Morice MC; Mack MJ; Holmes DR; Curzen N; Davierwala P; Noack T; Milojevic M; Dawkins KD; da Costa BR; Jüni P; Head SJ;
    Lancet; 2019 Oct; 394(10206):1325-1334. PubMed ID: 31488373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second vs. first-generation drug-eluting stents in complex lesions subsets: 3 years' follow-up of ERACI IV study.
    Rodriguez AE; Santaera O; Larribau M; Sarmiento R; Haiek C; Del Pozo JF; Pavlovsky H; Rodriguez-Granillo AM;
    Minerva Cardioangiol; 2017 Feb; 65(1):81-90. PubMed ID: 27784884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS).
    Morice MC; Feldman TE; Mack MJ; Ståhle E; Holmes DR; Colombo A; Morel MA; van den Brand M; Serruys PW; Mohr F; Carrié D; Fournial G; James S; Leadley K; Dawkins KD; Kappetein AP
    EuroIntervention; 2011 Oct; 7(6):670-9. PubMed ID: 21959312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.